Page 3 - Thyroid Associated News Today

-- Data presented at ENDO 2022 indicates low rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes ---- A separate poster presentation examined response to TEPEZZA in patients who were mildly hypothyroid and found outc...

-- Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease (TED) -- -- Three-time Olympic gold medalist Gail Devers will

-- Nationwide campaign spotlights mental health impact of living with TED -- For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (Nasdaq: HZNP) is partnering

-- Teprotumumab is marketed under the brand name TEPEZZA in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical

-- Comprehensive OPTIC-X trial results published in Ophthalmology, including new long-term follow-up data Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term

(0) -- TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline -- -- For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 percent had a proptosis response, 69 percent had a diplopia response and 83 percent had an ophthalmic composite outcome response -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZ...